BC Week In Review | Apr 13, 2018
Company News

pSivida acquires Icon, rebrands to EyePoint

EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT; ASX:PVA) (formerly pSivida Corp.) acquired Icon Bioscience Inc. (Newark, Calif.) and rebranded under a new name and ticker. EyePoint gained Icon's Dexycu dexamethasone intraocular suspension 9%, which received FDA approval in...
BC Week In Review | Feb 16, 2018
Clinical News

pSivida reports Phase III data for Durasert in posterior segment uveitis

pSivida Corp. (NASDAQ:PSDV; ASX:PVA) reported additional data from a Phase III trial in 153 patients with chronic, non-infectious posterior segment uveitis showing that intravitreal Durasert significantly reduced the recurrence of uveitis in the study eye...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Week In Review | Jul 13, 2017
Clinical News

pSivida submits MAA to EMA for Durasert

pSivida Corp. (NASDAQ:PSDV; ASX:PVA) submitted an MAA to EMA for Durasert to treat posterior segment uveitis. The company says it is in discussions to out-license the 3-year sustained-release fluocinolone acetonide treatment, and hopes to pin...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
BioCentury | Apr 7, 2017
Finance

To market, to market

Investors are hoping that a slew of approvals and data readouts can maintain biotech’s momentum on the heels of several high-profile successes that came just before or after 1Q’s end. Chief among those was Vertex...
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
BC Week In Review | Oct 10, 2016
Clinical News

Medidur fluocinolone acetonide intravitreal implant: Completed Phase III enrollment

pSivida completed enrollment of 150 patients in a double-blind, sham-controlled, Indian Phase III trial evaluating 0.18 mg intravitreal Medidur. The product uses the same micro-insert and corticosteroid as Iluvien fluocinolone acetonide intravitreal implant to treat...
BioCentury | Oct 3, 2016
Finance

Dressed in black

Every single market cap band finished in the black in 3Q16, a feat not accomplished since the first quarter of 2014. M&A and a string of positive clinical and regulatory news fueled the 3Q16 rally...
BC Extra | Sep 16, 2016
Company News

Management tracks

EMA said Head of International Affairs Emer Cooke will leave the agency to join the World Health Organization as head of regulation of medicines and other health technologies in WHO's essential medicines and health products...
Items per page:
1 - 10 of 222
BC Week In Review | Apr 13, 2018
Company News

pSivida acquires Icon, rebrands to EyePoint

EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT; ASX:PVA) (formerly pSivida Corp.) acquired Icon Bioscience Inc. (Newark, Calif.) and rebranded under a new name and ticker. EyePoint gained Icon's Dexycu dexamethasone intraocular suspension 9%, which received FDA approval in...
BC Week In Review | Feb 16, 2018
Clinical News

pSivida reports Phase III data for Durasert in posterior segment uveitis

pSivida Corp. (NASDAQ:PSDV; ASX:PVA) reported additional data from a Phase III trial in 153 patients with chronic, non-infectious posterior segment uveitis showing that intravitreal Durasert significantly reduced the recurrence of uveitis in the study eye...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Week In Review | Jul 13, 2017
Clinical News

pSivida submits MAA to EMA for Durasert

pSivida Corp. (NASDAQ:PSDV; ASX:PVA) submitted an MAA to EMA for Durasert to treat posterior segment uveitis. The company says it is in discussions to out-license the 3-year sustained-release fluocinolone acetonide treatment, and hopes to pin...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
BioCentury | Apr 7, 2017
Finance

To market, to market

Investors are hoping that a slew of approvals and data readouts can maintain biotech’s momentum on the heels of several high-profile successes that came just before or after 1Q’s end. Chief among those was Vertex...
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
BC Week In Review | Oct 10, 2016
Clinical News

Medidur fluocinolone acetonide intravitreal implant: Completed Phase III enrollment

pSivida completed enrollment of 150 patients in a double-blind, sham-controlled, Indian Phase III trial evaluating 0.18 mg intravitreal Medidur. The product uses the same micro-insert and corticosteroid as Iluvien fluocinolone acetonide intravitreal implant to treat...
BioCentury | Oct 3, 2016
Finance

Dressed in black

Every single market cap band finished in the black in 3Q16, a feat not accomplished since the first quarter of 2014. M&A and a string of positive clinical and regulatory news fueled the 3Q16 rally...
BC Extra | Sep 16, 2016
Company News

Management tracks

EMA said Head of International Affairs Emer Cooke will leave the agency to join the World Health Organization as head of regulation of medicines and other health technologies in WHO's essential medicines and health products...
Items per page:
1 - 10 of 222